Could Cyclacel Pharmaceuticals Inc (CYCC) Recover After Today’s Big Decline?

July 17, 2017 - By Richard Conner

Investors sentiment is 0 in Q4 2016. Its the same as in 2016Q3. It is without change, as 0 investors sold Cyclacel Pharmaceuticals Inc shares while 1 reduced holdings. only 0 funds opened positions while 0 raised stakes. 13,286 shares or 2.21% less from 13,586 shares in 2016Q3 were reported.
Baker Bros Advisors Ltd Partnership invested in 13,253 shares. 33 are held by Tower Capital Limited Liability (Trc).

The stock of Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC) is a huge mover today! About 977,500 shares traded or 1374.76% up from the average. Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC) has risen 10.62% since July 18, 2016 and is uptrending. It has underperformed by 6.08% the S&P500.
The move comes after 5 months negative chart setup for the $12.66M company. It was reported on Jul, 17 by Barchart.com. We have $3.17 PT which if reached, will make NASDAQ:CYCC worth $506,400 less.

More notable recent Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC) news were published by: Benzinga.com which released: “Adam Feuerstein Unloads On Cyclacel Pharmaceuticals, Will Break Down Its …” on April 04, 2017, also Seekingalpha.com with their article: “Cyclacel Pharmaceuticals: The Devil’s Advocate Be Damned” published on June 04, 2014, Schaeffersresearch.com published: “Cyclacel Pharmaceuticals Inc (CYCC) Spikes On Tang Capital Stake” on August 22, 2016. More interesting news about Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC) were released by: Marketwatch.com and their article: “3.51” published on September 11, 2009 as well as Seekingalpha.com‘s news article titled: “Cyclacel’s Date With Decitabine” with publication date: August 22, 2016.

Cyclacel Pharmaceuticals, Inc. operates in the field of cell cycle biology. The company has market cap of $12.66 million. The Firm has generated various families of anticancer drugs that act on the cell cycle, including nucleoside analogs, cyclin dependent kinase inhibitors, polo-like kinase (PLK) inhibitors and Aurora Kinase/vascular endothelial growth factor receptor (AK/VEGFR) inhibitors. It currently has negative earnings. The Company’s family of anticancer drugs that act on the cell cycle include sapacitabine, seliciclib and CYC065.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: